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Abstract
To control blood glucose level as close to normal is a major goal of treatment of diabetes mellitus. Hyperglycemia and hyperlipidemia are the
major risk factors for cardiovascular complications, the major cause of immature death among the patients with type 2 diabetes. The purpose of
this study is to determine the hypoglycemic and hypolipidemic effects of Salicornia herbacea in animal model of type 2 diabetes and to investigate
the possible mechanisms for the beneficial effects of S. herbacea. S. herbacea was extracted with 70% ethanol and desalted with 100% ethanol.
Three week-old db/db mice (C57BL/KsJ, n=16) were fed AIN-93G semipurified diet or diet containing 1% desalted ethanol extract of S. herbacea
for 6 weeks after 1 week of adaptation. Fasting plasma glucose, triglyceride, and total cholesterol were measured by enzymatic methods and blood
glycated hemoglobin (HbA1C) by the chromatographic method. Body weight and food intake of S. herbacea group were not significantly different 
from those of the control group. Fasting plasma glucose and blood glycated hemoglobin levels tended to be lowered by S. herbacea treatment. 
Consumption of S. herbacea extract significantly decreased plasma triglyceride and cholesterol levels (p<0.05). The inhibition of S. herbacea extract
against yeast α-glucosidase was 31.9% of that of acarbose at the concentration of 0.5 mg/mL in vitro. The inhibitory activity of ethanol extract 
of  S. herbacea against porcine pancreatic lipase was 59.0% of that of orlistat at the concentration of 0.25 mg/mL in vitro. Thus, these results 
suggest that S. herbacea could be effective in controlling hyperlipidemia by inhibition of pancreatic lipase in animal model of type 2 diabetes.
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Introduction19)
Diabetes mellitus is characterized by chronic hyperglycemia 
with disturbances of carbohydrate, fat and protein metabolism 
resulting from defects in insulin secretion, insulin action, or both. 
Cardiovascular disease (CVD) is a major complication and the 
leading cause of premature death among patients with diabetes 
(Centers for Disease Control and Prevention, 1999). The primary 
risk factor for CVD among patients with type 1 diabetes is 
hyperglycemia, although other risk factors, such as hypertension 
and dyslipidemia, may occur secondary to uncontrolled hypergly-
cemia (Bate & Jerums, 2003). In contrast, the pathophysiology 
of cardiovascular complications of type 2  diabetes involves 
elements of hyperglycemia, dyslipidemia, hypertension, and obe-
sity. It was also reported that tight control of hyperglycemia and 
aggressive therapeutic treatment of diabetic dyslipidemia are 
associated with the reduced risk of CVD in diabetic patients 
(American Diabetes Association, 2003). Although there have 
been enormous improvements in medication, strategy to cure 
diabetes mellitus completely has not been established so far. 
Therefore, numerous studies have been carried out to evaluate 
natural products, including plant materials, as alternative treat-
ments for diabetes to be used in addition to conventional 
treatments (Bailey & Day, 1989). 
In line of remedy from natural substances, it was reported that 
Salicornia herbacea L. could exert hypoglycemic and hypo-
lipidemic effects. S. herbacea is an annual herb growing in the 
salt mashes and on the muddy seashores. Ethanol extract of S. 
herbacea was found to prevent the onset of the hyperlipidemia 
induced by high fat diet in mice (Park et al., 2006). S. herbacea 
powder supplementation decreased blood glucose and triglyceride 
levels in streptozotocin (STZ)-induced diabetic rats (Bang et al., 
2002; Kim, 2007a). Consumption of water extract of enzyme- 
treated S. herbacea showed hypocholesterolemic effect in rat fed 
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high cholesterol diet (Kim et al., 2006). S. herbacea was also 
reported to have strong antioxidative effect in vitro (Lee et al., 
2004; Oh et al., 2007) and in vivo (Bang et al., 2002; Jang et 
al., 2007; Kim, 2007b). Since oxidative stress generated by free 
radical species plays a major role in the progression of diabetes 
(Kaneto  et al., 2005), S. herbacea could be beneficial for the 
prevention and treatment of diabetes via its antioxidative effects. 
However, the beneficial effects of S. herbacea on carbohydrate 
and lipid metabolism in type 2 diabetes were not studied. 
Therefore, the present study was aimed to investigate the effect 
of S. herbacea on hyperglycemia and hyperlipidemia in animal 
model of type 2 diabetes mellitus.
Materials and Methods 
Reagents 
Assay kits for glucose, cholesterol, and triglyceride were 
purchased from Asan Co (Seoul, South Korea) and a glycated 
hemoglobin (HbA1C) assay kit from BioSystems (Barcelona, 
Spain). Cornstarch was acquired from Daesang Co. (Seoul, 
Korea). Casein, L-cystine, mineral mixture, and vitamin mixture 
were purchased from ICN Pharmaceuticals Inc. (Costa Mesa, CA, 
USA) and tert-butyl hydroquinone from Fluka Co. (Milwaukee, 
WI, USA). Sucrose and soybean oil were obtained from Cheil-
jedang Co. (Seoul, Korea). Acarbose and orlistat were purchased 
from Bayer Korea (Seoul, Korea) and Roche Korea Co. (Seoul, 
Korea), respectively. Yeast α-glucosidase, porcine pancreatic 
lipase, p-nitropheny-α-D-glucopyranoside, 4-methylumbelliferyl 
oleate (4-MU oleate), and all other reagent grade chemicals were 
purchased from Sigma Chemical Co (St. Louis, MO, USA).
Preparation of the desalted ethanol extract
S. herbacea was obtained from a local market in Busan, Korea. 
S. herbacea was freeze-dried, powdered and extracted with ten 
volumes of 70% ethanol for 12 h three times at room temperature. 
The solvent was removed by rotary evaporation at 50℃. The 
dry extract was redissolved in 200 volumes of 100% ethanol 
and filtered using filter paper (No. 2, Whatman Inc., Florham 
Park, NJ, USA). The solvent was removed by rotary evaporation 
at 50℃. The yield of the desalted ethanol extract of S. herbacea 
was 4.2%. The dry extract was used for in vivo study and 
redissolved in dimethylsulfoxide (DMSO) to be used as a test 
material for the in vitro study.
Animals and experimental design
Three-week-old male C57BL/KsJ db/db mice (n=16) were 
purchased from the Korea Research Institute of Bioscience and 
Biotechnology (Daejeon, South Korea). After 1 week of 
adaptation during which the animals had free access to com-
mercial chow, they were randomly divided into a control and 
a S. herbacea group. The mice in the control group were offered 
a standard AIN-93G diet, which contained 39.8% cornstarch, 
20% casein, 13.2% dextrinized cornstarch, 10% sucrose, 7% 
soybean oil, 5% Alphacel, 3.5% mineral mixture, 1% vitamin 
mixture, 0.3% l-cystine, 0.25% choline bitartrate, and 0.0014% 
tert-butyl hydroquinone, whereas the S. herbacea group was 
offered the same diet supplemented with 1% (wt/wt, final 
concentration) of ethanol extract of S. herbacea ad libitum for 
6 weeks. The mice were housed individually in plastic cages 
and located in a room where temperature (23-27℃), humidity 
(50-60%), and lighting cycle (0600-1800 hr light and 1800-0600 
hr dark) were controlled. Body weight and food intake were 
measured three times a week. At the end of the experimental 
period, the mice were sacrificed by heart puncture after an 
overnight fast. Blood HbA1C levels were measured by the 
chromatographic method using a commercial assay kit. Blood 
samples were centrifuged at 3000 × g for 15 min; plasma was 
removed and frozen at -70℃ for further analysis. Plasma glucose, 
triglyceride, and total cholesterol were measured by enzymatic 
methods using commercial assay kits. The experiments were 
performed according to the guidelines of animal experimentation 
approved by the Animal Resource Center at Inje University, 
Korea.
Enzyme inhibition assay
Yeast α-glucosidase inhibitory activity was measured by the 
chromogenic method developed by Watanabe et al. (1997) using 
a microplate reader (model 550, Bio-Rad, Hercules, CA, USA). 
Yeast  α-glucosidase (0.7 U) dissolved in 100 mM phosphate 
buffer (pH 7.0) containing 2 g/L bovine serum albumin and 0.2 
g/L NaN3 and 5 mM p-nitrophenyl-α-D-glucopyranoside in the 
same buffer (pH 7.0) were used as an enzyme and a substrate 
solution, respectively. The final concentration of the S. herbacea 
extract and acarbose, a positive control, was 0.5 mg/mL. The 
measurement was performed in triplicate. 
The inhibitory activity against pancreatic lipase was measured 
by using 4-MU oleate as a substrate (Bitou et al., 1999). Porcine 
lipase (25 µL) was added to the reaction mixture which consisted 
of 50 µL of 0.1 mM 4-MU oleate, 20 µL of a McIlvane buffer 
(0.1 M citrate-Na2 HPO4, pH 7.4) and 5 µL of a sample solution. 
After the final volume was adjusted to 0.1 mL, the reaction 
mixture was incubated at 37℃ for 10 min. The amount of 4-MU 
released by the lipase was measured using fluorescence 
multi-detection reader (Bio-Tek Instruments, Inc., Winooski, VT, 
USA) at an excitation wavelength of 320 nm and an emission 
wavelength of 450 nm. The final concentration of the S. herbacea 
extract and orlistat, a positive control, was 0.25 mg/mL. The 
measurement was performed in triplicate.
Statistical analysis 
All values were expressed  as mean ± standard deviation 
(SD). All statistical analyses were performed using SAS (version Ji-Yeon Hwang et al. 373
Table 2. Inhibitory activities of the ethanol extract of S. herbacea on yeast α
-glucosidase and porcine pancreatic lipase
α-Glucosidase inhibitory 
activities (%)
Pancreatic lipase inhibitory 
activities (%)
S. herbacea extract 10.2 ± 0.5 56.2 ± 0.4
Acarbose 31.8 ± 0.4 -
Orlistat - 95.4 ± 0.3
Values  represent  mean ± SD
Table 1. Body weight, food intake, and feed efficiency ratio of the animals
Control S. herbacea group
Initial body weight (g) 25.4 ± 2.5 24.4 ± 3.0
ns
Final body weight (g) 39.3 ± 1.7 40.0 ± 2.6
ns
Body weight gain (g/d)  0.33 ± 0.04  0.37 ± 0.07
ns
Food intake (g/d)  4.8 ± 0.4  5.0 ± 0.3
ns
Feed efficiency ratio (%)*  7.0 ± 1.0  7.5 ± 1.1
ns
Values  represent  mean ± SD  (n=8)
*  Feed  efficiency  ratio  (%)=(body  weight  gain  (g)/food  intake  (g))×100
nsNot  significant
Fig. 1. Effect of S. herbacea extract on the levels of fasting blood glucose 
of db/db mice. Values  are  mean ± SD. 
nsNot  significant.
Fig. 2. Effect of S. herbacea extract on the levels of glycated hemoglobin 
(HbA1c) of db/db mice. Values  are  mean ± SD. 
nsNot  significant.
Fig. 3. Effect of S. herbacea extract on the levels of plasma triglyceride of 
db/db mice. Values  are  mean ± SD.  *p＜0.05.
Fig. 4. Effect of S. herbacea extract on the levels of plasma cholesterol of 
db/db mice. Values  are  mean ± SD.  *p＜0.05.
8.02). Differences between the control and S. herbacea groups 
were assessed by Student's t-test and significance was defined 
at p<0.05. 
Results
Body weight and food intake of the mice are shown in Table 
1. Chronic consumption of S. herbacea extract at the level of 
1% of the diet did not significantly influence body weight, food 
intake and feed efficiency ratio in db/db mice. The effect of S. 
herbacea  extract on glycemic control is shown in Fig. 1 and 
2. The fasting plasma glucose level of the S. herbacea group 
(509.7 ± 40.9 mg/dL) tended to be lowered compared with the 
control group (535.6 ± 35.4 mg/dL, Fig. 1). Blood glycated 
hemoglobin level of S. herbacea group (7.8 ± 1.0%) was not 
significantly different from the control group (8.1 ± 1.2%, Fig. 
2). The effect of S. herbacea extract on lipid profile is shown 
in Fig. 3 and 4. Consumption of S. herbacea extract significantly 
decreased plasma triglyceride (152.7 ± 21.0 mg/dL, Fig. 3) and 
total cholesterol levels (205.7 ± 22.1 mg/dL, Fig. 4) compared 
with the control group (180.7 ± 26.7 mg/dL and 233.5 ± 25.2 
mg/dL, respectively, p<0.05). 
The inhibitory activities of the ethanol extract of S. herbacea 
against yeast α-glucosidase and porcine pancreatic lipase are 
shown in Table 2. The ethanol extract of S. herbacea inhibited 374 Hypolipidemic Effect of S. herbacea
yeast α-glucosidase activity by 10.2% at the concentration of 
0.5 mg/mL in vitro.  Acarbose, an α-glucosidase inhibitor, which 
is used for an oral hypoglycemic agent inhibited the enzyme 
activity by 31.8%.  Inhibitory activities of S. herbacea extract 
against porcine pancreatic lipase were 56.2% at the concentration 
of 0.25 mg/mL. Orlistat, a pancreatic lipase inhibitor, showed 
inhibition of 95.4% at the same concentration. 
Discussion 
S. herbacea has been shown to exert hypoglycemic and 
hypolipidemic effects in rodents fed a high fat diet or in animal 
models of type 1 diabetes (Bang et al., 2002; Kim et al., 2006; 
Kim, 2007a). However, its hypoglycemic and hypolipidemic 
effects in animal model of type 2 diabetes have not been reported. 
Achieving near-normal glycemic control and lowering plasma 
lipid levels lead to a decrease in the risk of cardiovascular 
complications of diabetes which is the leading cause of premature 
death of patients with type 2 diabetes (UKPDS, 1998). In this 
study we determined antidiabetic effect of S. herbacea in db/db 
mice which exhibit type 2 diabetes and obesity. Consumption 
of ethanol extract of S. herbacea led to a significant decrease 
in plasma triglyceride and cholesterol. S. herbacea extract 
showed strong inhibitory activity against porcine pancreatic 
lipase in vitro. Inhibitory activity of S. herbacea extract against 
pancreatic lipase was 59.0% of that of orlistat at the concentration 
of 0.25 mg/mL in vitro. Inhibitor of pancreatic lipase could 
interfere with digestion of dietary triglycerides and retard 
absorption of fatty acids (Ballinger & Peikin, 2002). Chronic 
consumption of orlistat, a potent inhibitor of pancreatic lipase, 
reduced body weight, plasma triglyceride and cholesterol in obese 
patients (Lucas et al., 2003). In this study, S. herbacea with 
pancreatic lipase inhibitory activity showed triglyceride and 
cholesterol-lowering effect but did not influence body weight 
significantly in db/db mice. Dioscorea nipponica Makino (Kwon 
et al., 2003) and onion skin extract (Kim, 2007c) with pancreatic 
lipase inhibitory activity also decreased blood triglyceride and 
cholesterol in rats fed high fat diet. Orlistat has been reported 
to show side effects such as diarrhea (Ballinger & Peikin, 2002). 
Thus natural product with lipase inhibitory activity without side 
effects such as S. herbacea could be useful hypolipidemic agents 
which could reduce risks for diabetic complications.  Plasma 
glucose and blood glycated hemoglobin levels of S. herbacea 
group tended to be decreased compared with the control group, 
but the differences between the two groups were not significant. 
It was reported that S. herbacea powder supplementation at the 
level of 5% of the diet showed hypoglycemic effect in 
STZ-induced diabetic rats (Bang et al., 2002). Kim reported 
supplementation of S. herbacea powder at the level of 20% of 
the diet significantly decreased blood glucose in STZ-induced 
diabetic rats and suggested that dietary fiber contained in S. 
herbacea could be responsible for the hypoglycemic effect 
(2007a). However, consumption of ethanol extract of S. herbacea 
did not affect glycemic control in db/db mice in this study. S. 
herbacea extract showed mild inhibitory activity against yeast 
α-glucosidase in vitro. Inhibitory activity of S. herbacea extract 
against  α-glucosidase was 31.9% of that of acarbose at the 
concentration of 0.5 mg/mL in vitro. It appears that the hypo-
glycemic effect of S. herbacea could be stronger than that of 
S. herbacea extract if dietary fiber is the active component 
exerting hypoglycemic effect. 
In conclusion, ethanol extract of S. herbacea reduced plasma 
triglyceride and cholesterol in animal models of type 2 diabetes 
and the hypolipidemic effect could be partly due to inhibitory 
activity against pancreatic lipase. 
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